Biomet starts tennis elbow trial
This article was originally published in Clinica
Biomet Biologics has completed enrolment of 230 patients in the trial of its Recover platelet separation kit. This kit processes a sample of a patient's blood to produce autologous platelet-rich plasma to treat chronic lateral epicondylitis, also known as tennis elbow. The randomised, double-blind trial is being performed under a US FDA-approved Investigational Device Exemption (IDE) and is expected to conclude in mid-2011. Study participants will receive either the Biomet treatment or the local anaesthetic bupivacaine. The researchers will assess adverse events, severity of pain and arm function. The data from this pivotal study will support an approval submission to the US FDA. Biomet Biologics is a subsidiary of Warsaw, Indiana-based Biomet.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.